Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial

Fineline Cube Dec 14, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...

Company Drug

Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting

Fineline Cube Dec 14, 2022

China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...

Company Medical Device

Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation

Fineline Cube Dec 14, 2022

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...

Policy / Regulatory

Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues

Fineline Cube Dec 13, 2022

The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...

Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Company Drug

Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment

Fineline Cube Dec 13, 2022

China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...

Company Deals

Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M

Fineline Cube Dec 13, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...

Company Medical Device

Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia

Fineline Cube Dec 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...

Company Drug

Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting

Fineline Cube Dec 13, 2022

China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...

Company R&D

ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform

Fineline Cube Dec 13, 2022

Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...

Company Deals

Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...

Company Drug

JW Therapeutics Presents Carteyva Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...

Company Deals

4B Technologies Raises RMB 100M in Pre-Series B Financing Round

Fineline Cube Dec 13, 2022

China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...

Company Deals

Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share

Fineline Cube Dec 13, 2022

China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong...

Company Policy / Regulatory

Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling

Fineline Cube Dec 13, 2022

Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the...

Company Drug

Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...

Company Deals

HitGen and Nitrase Therapeutics Enter Research Agreement

Fineline Cube Dec 12, 2022

China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc....

Posts pagination

1 … 609 610 611 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.